North China Pharmaceutical Co Ltd (600812) — Cash Flow Reinvestment Rate
North China Pharmaceutical Co Ltd (600812) has a Cash Flow Reinvestment Rate of 0.85x as of September 2025, reinvesting CN¥144.38 Million (capex CN¥144.38 Million ) from operating cash flow of CN¥170.24 Million. Explore North China Pharmaceutical Co Ltd capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
North China Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2000–2025)
Historical reinvestment intensity for North China Pharmaceutical Co Ltd across 22 annual periods. Also explore North China Pharmaceutical Co Ltd total assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for North China Pharmaceutical Co Ltd (2000–2025)
Year-by-year capital reinvestment analysis for North China Pharmaceutical Co Ltd. For live market cap and broader valuation context, see 600812 market cap.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.66x | CN¥781.54 Million | CN¥1.18 Billion | CN¥542.01 Million | ▼ -44.0% |
| 2024 | 1.19x | CN¥1.46 Billion | CN¥1.23 Billion | CN¥784.22 Million | ▼ -19.3% |
| 2023 | 1.47x | CN¥1.50 Billion | CN¥1.02 Billion | CN¥623.04 Million | ▲ +167.5% |
| 2022 | 0.55x | CN¥551.58 Million | CN¥1.00 Billion | CN¥549.58 Million | ▼ -26.8% |
| 2021 | 0.75x | CN¥787.50 Million | CN¥1.05 Billion | CN¥547.50 Million | ▼ -44.1% |
| 2020 | 1.34x | CN¥1.01 Billion | CN¥752.15 Million | CN¥1.01 Billion | ▲ +51.7% |
| 2019 | 0.88x | CN¥648.46 Million | CN¥732.97 Million | CN¥645.97 Million | ▲ +34.6% |
| 2018 | 0.66x | CN¥509.13 Million | CN¥774.33 Million | CN¥506.64 Million | ▼ -68.5% |
| 2017 | 2.09x | CN¥599.69 Million | CN¥287.25 Million | CN¥399.69 Million | ▼ -55.0% |
| 2015 | 4.64x | CN¥567.81 Million | CN¥122.50 Million | CN¥367.81 Million | ▲ +62.5% |
| 2014 | 2.85x | CN¥258.30 Million | CN¥90.56 Million | CN¥258.30 Million | ▼ -42.9% |
| 2011 | 4.99x | CN¥1.14 Billion | CN¥227.60 Million | CN¥1.14 Billion | ▲ +1279.5% |
| 2009 | 0.36x | CN¥366.10 Million | CN¥1.01 Billion | CN¥366.10 Million | ▲ +184.8% |
| 2008 | 0.13x | CN¥138.00 Million | CN¥1.09 Billion | CN¥138.00 Million | ▼ -14.1% |
| 2007 | 0.15x | CN¥98.27 Million | CN¥664.37 Million | CN¥98.27 Million | ▲ +70.8% |
| 2006 | 0.09x | CN¥51.72 Million | CN¥597.12 Million | CN¥51.72 Million | ▼ -89.5% |
| 2005 | 0.82x | CN¥184.67 Million | CN¥224.17 Million | CN¥184.67 Million | ▼ -26.6% |
| 2004 | 1.12x | CN¥348.50 Million | CN¥310.39 Million | CN¥348.50 Million | ▲ +47.2% |
| 2003 | 0.76x | CN¥442.77 Million | CN¥580.32 Million | CN¥442.77 Million | ▲ +150.8% |
| 2002 | 0.30x | CN¥224.68 Million | CN¥738.50 Million | CN¥224.68 Million | ▼ -41.7% |
| 2001 | 0.52x | CN¥191.79 Million | CN¥367.28 Million | CN¥191.79 Million | ▼ -28.5% |
| 2000 | 0.73x | CN¥97.52 Million | CN¥133.49 Million | CN¥97.52 Million | — |